G9839 HCPCS Level II code: Anti-egfr monoclonal antibody therapy
G9839 is the HCPCS code for “Anti-egfr monoclonal antibody therapy” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
G9839Anti-egfr monoclonal antibody therapy
Short description: Anti-egfr mon anti ther
HCPCS · United States
Medicare details
The indicators CMS publishes with G9839 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2017
Where G9839 sits
- 1G codesProcedures and professional services
- 2Active code G9839Anti-egfr monoclonal antibody therapy
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code G9839 mean?
G9839 is the HCPCS code for “Anti-egfr monoclonal antibody therapy” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover G9839?
CMS lists G9839’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9839
All G codesG9833Patient transfer to practice after initiation of chemotherapyG9834Patient has metastatic disease at diagnosisG9835Trastuzumab administered within 12 months of diagnosisG9836Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant…G9837Trastuzumab not administered within 12 months of diagnosisG9838Patient has metastatic disease at diagnosisG9840Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moabG9841Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moabG9842Patient has metastatic disease at diagnosisG9843Ras (kras or nras) gene mutationG9844Patient did not receive anti-egfr monoclonal antibody therapyG9845Patient received anti-egfr monoclonal antibody therapy